Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (20655)
All Articles published online
|
Feb 10, 2011 (publication date) through Nov 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Peng G, Lin SY. Exploiting the homologous recombination DNA repair network for targeted cancer therapy. World J Clin Oncol 2011; 2(2): 73-79 [PMID: 21603316 DOI: 10.5306/wjco.v2.i2.73] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v2/i2/73.htm |
| Number | Citing Articles |
| 1 |
Yuqiao Shen, Mika Aoyagi-Scharber, Bing Wang. Trapping Poly(ADP-Ribose) Polymerase. Journal of Pharmacology and Experimental Therapeutics 2015; 353(3): 446 doi: 10.1124/jpet.114.222448
|
| 2 |
B.L. Collins, A.N. Gonzalez, A. Hanbury, L. Ceppi, R.T. Penson. Translational Advances in Gynecologic Cancers. 2017; : 129 doi: 10.1016/B978-0-12-803741-6.00007-0
|
| 3 |
Cong Fan, Juan Zhang, Tao Ouyang, Jinfeng Li, Tianfeng Wang, Zhaoqing Fan, Tie Fan, Benyao Lin, Yuntao Xie. RAD50 germline mutations are associated with poor survival in BRCA1/2–negative breast cancer patients. International Journal of Cancer 2018; 143(8): 1935 doi: 10.1002/ijc.31579
|
| 4 |
Anas Ahmad, Ravi Prakash, Mohd Shahnawaz Khan, Nojood Altwaijry, Muhammad Nadeem Asghar, Syed Shadab Raza, Rehan Khan. Nanoparticle-Mediated PRDX2 Inhibition for Specific Targeting of CHK2-Null Colorectal Cancer. ACS Biomaterials Science & Engineering 2022; 8(12): 5210 doi: 10.1021/acsbiomaterials.2c01073
|
| 5 |
Linda Popplewell, Taeyoung Koo, Xavier Leclerc, Aymeric Duclert, Kamel Mamchaoui, Agnés Gouble, Vincent Mouly, Thomas Voit, Frédéric Pâques, Frédéric Cédrone, Olga Isman, Rafael J. Yáñez-Muñoz, George Dickson. Gene Correction of a Duchenne Muscular Dystrophy Mutation by Meganuclease-Enhanced Exon Knock-In. Human Gene Therapy 2013; 24(7): 692 doi: 10.1089/hum.2013.081
|
| 6 |
José Alexandre Ferreira, Andreia Peixoto, Manuel Neves, Cristiana Gaiteiro, Celso A. Reis, Yehuda G. Assaraf, Lúcio Lara Santos. Mechanisms of cisplatin resistance and targeting of cancer stem cells: Adding glycosylation to the equation. Drug Resistance Updates 2016; 24: 34 doi: 10.1016/j.drup.2015.11.003
|
| 7 |
Brent J. Guppy, Kirk J. McManus. Synthetic lethal targeting of RNF20 through PARP1 silencing and inhibition. Cellular Oncology 2017; 40(3): 281 doi: 10.1007/s13402-017-0323-y
|
| 8 |
Annalisa Mazzotta, Giulia Partipilo, Simona De Summa, Francesco Giotta, Giovanni Simone, Anita Mangia. Nuclear PARP1 expression and its prognostic significance in breast cancer patients. Tumor Biology 2016; 37(5): 6143 doi: 10.1007/s13277-015-4465-0
|
| 9 |
Gabriel S. Macedo, Barbara Alemar, Patricia Ashton-Prolla. Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era. Genetics and Molecular Biology 2019; 42(1 suppl 1): 215 doi: 10.1590/1678-4685-gmb-2018-0104
|
| 10 |
Kyung-Hee Song, Seung-Youn Jung, Jeong-In Park, Jiyeon Ahn, Jong Kuk Park, Hong-Duck Um, In-Chul Park, Sang-Gu Hwang, Hunjoo Ha, Jie-Young Song. Inhibition of Karyopherin-α2 Augments Radiation-Induced Cell Death by Perturbing BRCA1-Mediated DNA Repair. International Journal of Molecular Sciences 2019; 20(11): 2843 doi: 10.3390/ijms20112843
|
| 11 |
Daniel Olson, Savita Bhalla, Ximing Yang, Brenda Martone, Timothy M. Kuzel. Novel Use of Targeted Therapy via PARP-Inhibition in a Rare Form of Papillary Renal Cell Carcinoma: A Case Report and Literature Review. Clinical Genitourinary Cancer 2016; 14(4): e445 doi: 10.1016/j.clgc.2016.03.012
|
| 12 |
Justin Alexander Davis, Kausik Chakrabarti. Telomerase ribonucleoprotein and genome integrity—An emerging connection in protozoan parasites. WIREs RNA 2022; 13(5) doi: 10.1002/wrna.1710
|
| 13 |
Yann-Lii Leu, Shu-Fang Cheng, Tong-Hong Wang, Chun-Hao Feng, Yu-Ju Chen, Yi-Cheng Hsieh, Yu-Hsuan Lan, Chin-Chuan Chen. Increasing DNA damage sensitivity through corylin-mediated inhibition of homologous recombination. Biomedicine & Pharmacotherapy 2024; 176: 116864 doi: 10.1016/j.biopha.2024.116864
|
| 14 |
|
| 15 |
Ana Isabel Sánchez Bermúdez, M.ª Desamparados Sarabia Meseguer, Verónica Guardiola Castillo, Francisco Ruiz Espejo, José Antonio Noguera Velasco. RAD51C and RAD51D in the hereditary breast and ovarian cancer syndrome. Revista de Medicina de Laboratorio 2020; doi: 10.20960/revmedlab.00024
|
| 16 |
Haseeb Ahmad Khan, Abdullah Saleh Alhomida. A review of the logistic role of l‐carnitine in the management of radiation toxicity and radiotherapy side effects. Journal of Applied Toxicology 2011; 31(8): 707 doi: 10.1002/jat.1716
|
| 17 |
Nicholas A. Wallace, Sujita Khanal, Kristin L. Robinson, Sebastian O. Wendel, Joshua J. Messer, Denise A. Galloway, Lawrence Banks. High-Risk Alphapapillomavirus Oncogenes Impair the Homologous Recombination Pathway. Journal of Virology 2017; 91(20) doi: 10.1128/JVI.01084-17
|
| 18 |
Laura Mosca, Cristina Pagano, Roberta Veglia Tranchese, Roberta Grillo, Francesca Cadoni, Giovanna Navarra, Laura Coppola, Martina Pagano, Luigi Mele, Giovanna Cacciapuoti, Chiara Laezza, Marina Porcelli. Antitumoral Activity of the Universal Methyl Donor S-Adenosylmethionine in Glioblastoma Cells. Molecules 2024; 29(8): 1708 doi: 10.3390/molecules29081708
|
| 19 |
Wojciech Żwierełło, Agnieszka Maruszewska, Robert Nowak, Dorota Kostrzewa-Nowak, Jolanta Tarasiuk. DNA damage induced by NADPH cytochrome P450 reductase-activated idarubicin in sensitive and multidrug resistant MCF7 breast cancer cells. Pharmacological Reports 2017; 69(1): 185 doi: 10.1016/j.pharep.2016.10.002
|
| 20 |
Michela Palleschi, Gianluca Tedaldi, Marianna Sirico, Alessandra Virga, Paola Ulivi, Ugo De Giorgi. Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer. International Journal of Molecular Sciences 2021; 22(15): 7884 doi: 10.3390/ijms22157884
|
| 21 |
Heng-Wei Hsu, Rosalia de Necochea-Campion, Vonetta Williams, Penelope J. Duerksen-Hughes, Alfred A. Simental, Robert L. Ferris, Chien-Shing Chen, Saied Mirshahidi. Linifanib (ABT-869), enhances cytotoxicity with poly (ADP-ribose) polymerase inhibitor, veliparib (ABT-888), in head and neck carcinoma cells. Oral Oncology 2014; 50(7): 662 doi: 10.1016/j.oraloncology.2014.03.006
|
| 22 |
Yoshiko Oyama, Shogo Shigeta, Hideki Tokunaga, Keita Tsuji, Masumi Ishibashi, Yusuke Shibuya, Muneaki Shimada, Jun Yasuda, Nobuo Yaegashi, Carlos Telleria. CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of CHD4 inhibition as a combination therapy with platinum agents. PLOS ONE 2021; 16(6): e0251079 doi: 10.1371/journal.pone.0251079
|
| 23 |
Alexandra-Zoe Andrei, Anita Hall, Alyssa L. Smith, Claire Bascuñana, Abba Malina, Ashton Connor, Gulbeyaz Altinel-Omeroglu, Sidong Huang, Jerry Pelletier, David Huntsman, Steven Gallinger, Atilla Omeroglu, Peter Metrakos, George Zogopoulos. Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2 inhibitor BMN 673. Cancer Letters 2015; 364(1): 8 doi: 10.1016/j.canlet.2015.04.003
|
| 24 |
Jose Lucio, Irene Gonzalez-Jimenez, Alejandra Roldan, Jorge Amich, Laura Alcazar-Fuoli, Emilia Mellado. Importance of the Aspergillus fumigatus Mismatch Repair Protein Msh6 in Antifungal Resistance Development. Journal of Fungi 2024; 10(3): 210 doi: 10.3390/jof10030210
|
| 25 |
Irene Paterniti, Sarah Adriana Scuderi, Giovanna Casili, Marika Lanza, Marzia Mare, Raffella Giuffrida, Cristina Colarossi, Marco Portelli, Salvatore Cuzzocrea, Emanuela Esposito. Poly (ADP-Ribose) Polymerase Inhibitor, ABT888, Improved Cisplatin Effect in Human Oral Cell Carcinoma. Biomedicines 2021; 9(7): 771 doi: 10.3390/biomedicines9070771
|
| 26 |
Jasmin Volpe, Jennifer G. Filipi, Olivia R. Cooper, Richard T. Penson. Frontline therapy of ovarian cancer: trials and tribulations. Current Opinion in Obstetrics & Gynecology 2018; 30(1): 1 doi: 10.1097/GCO.0000000000000434
|
| 27 |
Christin Grabinski, Nicole Schaeublin, Andy Wijaya, Helen D’Couto, Salmaan H. Baxamusa, Kimberly Hamad-Schifferli, Saber M. Hussain. Effect of Gold Nanorod Surface Chemistry on Cellular Response. ACS Nano 2011; 5(4): 2870 doi: 10.1021/nn103476x
|
| 28 |
Denis Velic, Anthony Couturier, Maria Ferreira, Amélie Rodrigue, Guy Poirier, Fabrice Fleury, Jean-Yves Masson. DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles’ Heel of Cancer. Biomolecules 2015; 5(4): 3204 doi: 10.3390/biom5043204
|
| 29 |
Junyang Tan, Wenjun Wang, Xinjie Liu, Jinhong Xu, Yaping Che, Yanyan Liu, Jiaqiao Hu, Liubing Hu, Jianshuang Li, Qinghua Zhou. C11orf54 promotes DNA repair via blocking CMA-mediated degradation of HIF1A. Communications Biology 2023; 6(1) doi: 10.1038/s42003-023-04957-1
|
| 30 |
Peter J. Choi, Elizabeth Cooper, Patrick Schweder, Edward Mee, Clinton Turner, Richard Faull, William A. Denny, Mike Dragunow, Thomas I.-H. Park, Jiney Jose. PARP inhibitor cyanine dye conjugate with enhanced cytotoxic and antiproliferative activity in patient derived glioblastoma cell lines. Bioorganic & Medicinal Chemistry Letters 2020; 30(14): 127252 doi: 10.1016/j.bmcl.2020.127252
|
| 31 |
Anteneh A. Tesfaye, Mandana Kamgar, Asfar Azmi, Philip A. Philip. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. Expert Review of Anticancer Therapy 2018; 18(2): 131 doi: 10.1080/14737140.2018.1417844
|
| 32 |
Filip Janku, Ahmed O. Kaseb, Apostolia M. Tsimberidou, Robert A. Wolff, Razelle Kurzrock. Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. Oncotarget 2014; 5(10): 3012 doi: 10.18632/oncotarget.1687
|
| 33 |
Reza Soleimani, Elke Heytens, Zbigniew Darzynkiewicz, Kutluk Oktay. Mechanisms of chemotherapy-induced human ovarian aging: double strand DNA breaks and microvascular compromise. Aging 2011; 3(8): 782 doi: 10.18632/aging.100363
|
| 34 |
Donavon Hiss. Optimizing Molecular-Targeted Therapies in Ovarian Cancer: The Renewed Surge of Interest in Ovarian Cancer Biomarkers and Cell Signaling Pathways. Journal of Oncology 2012; 2012: 1 doi: 10.1155/2012/737981
|
| 35 |
Laura E. Knighton, Andrew W. Truman. Heat Shock Proteins in Signaling Pathways. Heat Shock Proteins 2019; 17: 345 doi: 10.1007/978-3-030-03952-3_18
|
| 36 |
Karen A Pooley, Alison M Dunning. DNA damage and hormone-related cancer: a repair pathway view. Human Molecular Genetics 2019; 28(R2): R180 doi: 10.1093/hmg/ddz206
|
| 37 |
Avital Lev, Safoora Deihimi, Elena Shagisultanova, Joanne Xiu, Amriti R. Lulla, David T. Dicker, Wafik S. El-Deiry. Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer. Cancer Biology & Therapy 2017; 18(9): 694 doi: 10.1080/15384047.2017.1364323
|
| 38 |
Yiren Yang, Pengyu Liu, Mingyang Zhou, Linzhou Yin, Miao Wang, Ting Liu, Xiaowen Jiang, Huiyuan Gao. Small-molecule drugs of colorectal cancer: Current status and future directions. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2024; 1870(1): 166880 doi: 10.1016/j.bbadis.2023.166880
|